BlackRock, Inc. Reports 5.7% Stake in Mirum Pharmaceuticals, Inc. via Schedule 13G/A

BlackRock, Inc. has filed a Schedule 13G/A with the SEC, dated April 27, 2026, disclosing a significant increase in its position in Mirum Pharmaceuticals, Inc (MIRM). As of the event date on March 31, 2026, BlackRock reported beneficial ownership of 3,465,559 shares of common stock, representing a 5.7% ownership stake in the company. This marks a substantial increase from a previous reported position of zero shares, indicating a new major holding by the institutional investor. The filing specifies that BlackRock holds sole voting power over 3,404,101 shares and sole dispositive power over the full 3,465,559 shares. The acquisition was made in the ordinary course of business and not for the purpose of influencing or changing the control of the issuer. Various subsidiaries under the BlackRock parent company are identified as participating in the ownership, though no individual person's interest exceeds five percent of the total outstanding common shares. The filing was signed by Spencer Fleming, Managing Director, and reflects the disaggregated reporting structure of BlackRock's various business units.